Endoscopy 2019; 51(04): S159-S160
DOI: 10.1055/s-0039-1681641
ESGE Days 2019 ePoster podium presentations
Friday, April 5, 2019 16:30 – 17:00: Bariatric ePoster Podium 1
Georg Thieme Verlag KG Stuttgart · New York

EVALUATION OF FREQUENCY OF VOMITING AND THE NEED FOR HOSPITAL SUPPORT AFTER PLACEMENT OF THE INTRAGASTRIC BALLOON (IGB)

S Barrichello
1   Bariatric Endoscopy, Healthme Weight Management Clinic, São Paulo, Brazil
,
GC Nunes
2   Nutrition, Hospital das Clinicas da Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil
,
AC Hoff
3   Bariatric Endoscopy, Angioskope Clinic, São José dos Campos, Brazil
,
JR Fernandes Fittipaldi
4   Bariatric Endoscopy, Endogastrorio Clinic, Rio de Janeiro, Brazil
,
T Ferreira de Souza
5   Bariatric Endoscopy, FMABC, Santo André, Brazil
,
J Waisberg
5   Bariatric Endoscopy, FMABC, Santo André, Brazil
,
M Galvão Neto
5   Bariatric Endoscopy, FMABC, Santo André, Brazil
,
A Fabio Teixeira
6   Bariatric Endoscopy, Gastros Bahia Clinic, Vitoria da Conquista, Brazil
,
E Nobuki Usuy
7   Bariatric Endoscopy, Usuy Clínica Médica, Florianopolis, Brazil
,
J Scarparo
8   Bariatric Endoscopy, Scarparo Scopia, Sao Paulo, Brazil
,
E Guimaraes Hourneax de Moura
9   Bariatric Endoscopy, Hospital das Clinicas da Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil
› Author Affiliations
Further Information

Publication History

Publication Date:
18 March 2019 (online)

Also available at
 

Aims:

One of the most widely used treatment options in Brazil is the implantation of a silicone intragastric balloon (IGB).

The most common side effects after implantation of an IGB are nausea, vomiting and dehydration. According to Scudero et al 71.1% of patients experienced nausea and 57.9% had vomiting. Regarded as one of the major causes of early withdrawal of the balloon, it is important to evaluate the frequency intravenous hydration required to quell nausea and vomiting during the first days of use of the accessory.

Methods:

Retrospective study, with analysis of medical records of 340 obese and overweight patients treated with iIGBs between November 2014 and December 2016 in the bariatric endoscopy division of a private clinic in São Paulo.

The patients used omeprazole 40 mg once a day, as well as antiemetic drugs compulsorily for the first 5 days.

The data recorded were the number and frequency of vomiting and whether there was a need for intravenous hydration in the first three days after implantation of the iIGB.

Results:

The sample consisted of adults, 84.11% of whom were women, with a mean age of 34.19 ± 6.16 years, a mean BMI of 36.94 ± 5.67 Kg/m2.

74.41% of our sample reported nausea and vomiting in the first three days after IGB placement. Among the patients who experienced vomiting, 67.58% presented a frequency of up to five times per day and 32.42% from five to ten times per day. Approximately 9.48% of the patients required intravenous hydration and there were no early IGB withdrawals.

Conclusions:

An endoscopic approach to obesity and excess weight with IGBs causes vomiting in the early days after implantation in 74.41% of patients and causes dehydration requiring intravenous fluid therapy in 7.06% of all patients who had IGBs implanted.